Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity
Trial ID or NCT#
Status
Purpose
The primary objective of this study is to determine the influence of insulin resistance on drug metabolism and response in obese subjects. The investigators hypothesize that expression of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin gene can predict the insulin resistance and drug response among obese subjects.
Official Title
Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity
Eligibility Criteria
- - Inclusion criteria include patients of adult age - American Society of Anesthesiologists Class I, II, or III, and undergoing elective surgical procedures requiring general anesthesia - Body mass index greater than 35
- - Patients with evidence of hepatic, renal, or cardiovascular dysfunction - History of difficult tracheal intubation, or adverse reaction to anesthesia shall be excluded from the study - Patients taking prescribed or over-the-counter anxiolytics, narcotics, or sleeping aids, will also be excluded
Contact us to find out if this trial is right for you.
Contact
Jerry Ingrande, M.D., M.S.
650-723-7377
View on ClinicalTrials.gov